Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 22 Dec 2021 for Finch Therapeutics Group, Inc., €578k.
Filing timeline
BuySaleNicholas Haft
Insider track record
Disclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-53.2%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
No signal scores available.
Nicholas Haft: trading record in brief
Nicholas Haft, listed as board member, appears in our data through filings on Finch Therapeutics Group, Inc. shares, published by SEC (Form 4). The record holds 8 filings, for trades running from 23 March 2021 to 20 December 2021.
Every open-market trade on record is a purchase: 2 purchases worth €13.1M, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
The latest filing, published on 22 December 2021, reports an open-market purchase of €578k in Finch Therapeutics Group, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Nicholas Haft
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations1 total
63,850 shares@ US$10.18100.0% of flowCommon Stock, $0.001 par value per shareSEC:0001567619-21-022453:0
Canonical exit: 20 Mar 2022 (T+90)
1 of 1 declaration
